跳至主要内容
临床试验/2023-505726-34-02
2023-505726-34-02尚未招募4 期

Studies to gain insight how the drugs PCSK9-inhibitors and statins affect cholesterol and bile acid metabolism

Karolinska University Hospital1 个研究点 分布在 1 个国家目标入组 8 人开始时间: 2024年4月12日最近更新:

试验速览

阶段
4 期
状态
尚未招募
发起方
入组人数
8
试验地点
1
主要终点
Changes in the measured parameters of cholesterol and bile acid metabolism

研究概览

简要总结

To learn more about the effects of the drugs statin (atorvastatin) and PCSK9 inhibitors (evolocumab) on the metabolism of cholesterol and bile acids in the human body.

入排标准

年龄范围
18 years 至 64 years(18-64 Years)
性别
Male
接受健康志愿者

入选标准

  • 18-64 year old

排除标准

  • Cardiovascular disease
  • Any chronic medication use
  • Steroid treatment for the last six months or HRT
  • Coagulopathy
  • Musculoskeletal or neurologic disease
  • Inclusion in any other concurrent medical research study
  • Cerebrovascular disease (e.g. stroke, prior aneurysm)
  • Pulmonary disease (e.g. pulmonary hypertension, COPD)
  • Metabolic disease (incl. but not limited to Cushing disease, Diabetes)
  • Renal disease (by CKD criteria)
  • Active inflammatory bowel syndrome

结局指标

主要结局

Changes in the measured parameters of cholesterol and bile acid metabolism

Changes in the measured parameters of cholesterol and bile acid metabolism

次要结局

未报告次要终点

研究者

发起方
Karolinska University Hospital
申办方类型
Hospital/Clinic/Other health care facility
责任方
Principal Investigator
主要研究者

Mats Eriksson

Scientific

Karolinska University Hospital

研究点 (1)

Loading locations...

相似试验